Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis
28 June 2022
Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.
OxCODE funding scheme awards 2022
24 June 2022
Congratulations to Sarah Blagden, Skirmantas Kriaucionis and their collaborators who have been awarded funding in the third round of the OxCODE Funding Scheme.
Largest study to date confirms role of two hormones in aggressive prostate cancer risk
23 June 2022
New, genetics and blood-based study links testosterone and insulin-like growth factor hormones to aggressive prostate cancer for the first time.
First DeLIVER study day
14 June 2022
On Wednesday 8th June 2022, the DeLIVER consortium gathered for the first time to hear about the team’s progress towards the aim of detecting liver cancer earlier.
National clinical study launched to test new technologies for detecting liver cancer
25 May 2022
The SELINA study will recruit patients with early liver cancers as part of the DeLIVER programme aiming to detect liver cancer earlier.
Early detection innovation award for Oxford researchers
17 May 2022
Professor Julia Hippisley-Cox and Dr Tingting Zhu win funding for their collaborative project on novel test technologies for patient triage in primary care.
Greater adiposity linked to increased risk of fatal prostate cancer
5 May 2022
A new Oxford study finds that greater body fat (adiposity) may increase the risk of dying from prostate cancer by up to 10%.
Predicting early recurrence of pancreatic cancer
3 May 2022
Dr Daniel Hughes and colleagues identify NUDT15 as a potential biomarker for pancreatic cancer recurrence following surgery.
Funding to study stomach cancer development
12 April 2022
Dr Francesco Boccellato receives a John Fell Fund award to investigate how the stomach lining changes shape during the transition from healthy tissue to cancer.
Automated assessment of pathology image quality
6 April 2022
The new Oxford-developed artificial intelligence tool PathProfiler automates the quality control of large retrospective pathology image datasets to increase their usability in downstream research.
Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology
5 April 2022
Optellum Virtual Nodule Clinic, including its proprietary artificial intelligence lung cancer prediction solution, has achieved CE certification under the European Union’s Medical Device Regulation.
Funding to develop a new device for breast cancer detection
4 April 2022
Professor Jason Davis has been awarded a Cancer Research UK Early Detection and Diagnosis Primer Award to develop a single-step, ultra-sensitive device for detecting breast cancer cells in the blood.
A new opportunity for myeloma early diagnosis
25 March 2022
Screening within a fracture clinic can expedite diagnoses of multiple myeloma and its precursor, MGUS.
Understanding AI-based lung nodule risk prediction
21 March 2022
The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.
Blood tests provide no additional information to FIT alone when prioritising patients for colorectal cancer referral
15 March 2022
Faecal immunochemical testing (FIT) alone leads to the identification of the same number of patients with colorectal cancer as more complicated approaches that combine the FIT result with the results of commonly used blood tests.
Adiposity in early life, but not adulthood, may protect against breast cancer
9 March 2022
New data from the Million Women Study indicates that adiposity at different life stages is likely to affect the risk of postmenopausal breast cancer through distinct mechanisms.
First major UK prospective study for liver cancer underway
24 February 2022
The Pearl clinical study will recruit 3000 patients with high-risk conditions for liver cancer with the aim of detecting liver cancer earlier as part of the Cancer Research UK-funded DeLIVER programme.
Comparing models to predict liver cancer in individuals with high-risk conditions
21 February 2022
Members of the DeLIVER consortium and their collaborators have tested the performance of hepatocellular carcinoma risk prediction models in patients with cirrhosis and cured hepatitis C infection.
Groundbreaking University of Oxford research could lead to early diagnosis of pancreatic cancer
27 January 2022
New research into the onset of diabetes which could go on to help in the early diagnosis of pancreatic cancer is being led by scientists at the University of Oxford.
Identifying protein biomarkers for pancreatic cancer
26 January 2022
Dr Christiana Kartsonaki and colleagues from the China Kadoorie Biobank have identified several proteins in the blood that are associated with an increased risk of pancreatic cancer.